1.

A mixed method study design to explore the adherence of haematological cancer patients to oral anticancer medication in a multilingual and multicultural outpatient setting: The MAD...

2.

A mixed method study design to explore the adherence of haematological cancer patients to oral anticancer medication in a multilingual and multicultural outpatient setting: The MAD...

3.

A mixed method study design to explore the adherence of haematological cancer patients to oral anticancer medication in a multilingual and multicultural outpatient setting: The MAD...

1.

Increasing Incidence of Mucormycosis in University Hospital, Belgium

1.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

2.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

3.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

4.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

5.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

6.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

7.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

1.

Characterization and risk factors of hyperglycaemia during treatment of childhood hematologic malignancies.

2.

Characterization and risk factors of hyperglycaemia during treatment of childhood hematologic malignancies.

3.

Characterization and risk factors of hyperglycaemia during treatment of childhood hematologic malignancies.

1.

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.

2.

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.

3.

The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.

1.

Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen.